Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

Executive Summary

During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.

Advertisement

Related Content

IPO Update: With No New Offerings, Kadmon Steals The Spotlight
IPO Update: Haircuts Needed To Price Biotech Offerings
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Biotech VC Funding Rises As Fewer Companies Get More Dollars
Mersana/Takeda Deal Adds To ADC Pipeline
INFOGRAPHIC: A US biotech IPO surge? Data are mixed
CRISPR Therapeutics raises $64m 'validating' uncertain patent position
Mersana raises $35m, names former Millennium president CEO
Elan veterans grab $34m for neurodegenerative diseases
Merck Serono enters antibody drug conjugate fray

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel